Think Tank Meeting Minutes/white papers (M6)

Task 1.1.3 Implementation of the Think Tank (M6-M24) (GSK, NICE, ZIN, UMCU, SARD, Takeda, Lilly, AZ, UCB, Bayer, Amgen, UMCG, LA-SER). Delivery date M6, 12, 18, 24 The appointed members of the Think Tank will convene periodically (virtual and/or in real-life) to enable scientific exchange, to prioritize RWE barriers and/or opportunities and to discuss results from the Task Forces. The outcomes of the Think Tank can lead to vision documents including priority areas for future research and policy recommendations. In the event that a new Task Force is recommended by the Think Tank, the EPMT will approve the initiation of activities and make the final decision. The Think Tank members will help define the scope of the Task Force, help identify Task Force Leaders, support the identification of Task Forces contributors. WP3 will work with the Task Force Leaders to define the timelines for delivery and allocate budget. The Think Tank will also review outputs from ongoing Task Forces and work with Task Forces (e.g. through consultations) to implement their dissemination and stakeholder engagement plan. Members of the Think Tank will act as global ambassadors for the outputs of the Task Forces. The outcomes of the meetings will be recorded (D1.2/D1.3/D1.4/D1.5). In addition to Task Forces, the Think Tank will also identify topics to be discussed in a broader scientific forum. It is envisaged that two large scientific meetings will be conducted throughout the duration of the current project. The model of these meetings will be based on the successful closing event of IMI GetReal in Brussels in November 2016 and the stakeholder round table in June 2016 in London. Project Management, event management and stakeholder engagement activities conducted by the Think Tank and Task Force Leaders will be supported by WP3.